(HCA) HCA Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US40412C1018
Stock: Hospitals, Surgery Centers, Emergency Clinics, Imaging Centers, Home Health
Total Rating 63
Risk 58
Buy Signal -0.58
| Risk 5d forecast | |
|---|---|
| Volatility | 28.0% |
| Relative Tail Risk | -4.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.50 |
| Alpha | 37.67 |
| Character TTM | |
|---|---|
| Beta | 0.588 |
| Beta Downside | 0.605 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.45% |
| CAGR/Max DD | 0.91 |
EPS (Earnings per Share)
Revenue
Description: HCA HCA Holdings February 24, 2026
HCA Healthcare, Inc. (NYSE: HCA) operates a nationwide network of acute-care hospitals, ambulatory surgery centers, urgent-care clinics, diagnostic imaging sites, oncology and rehabilitation facilities, as well as physician practices and home-health services. Founded in 1968 and headquartered in Nashville, Tennessee, the company delivers both inpatient and outpatient medical, surgical, and specialty care across the United States.
In its most recent fiscal year, HCA generated $58.7 billion in revenue, with an adjusted earnings-per-share of $5.40 and an operating margin of roughly 7.5%. The Q1 2024 earnings release showed a 4% year-over-year increase in net patient revenue and an occupancy rate of 78%, reflecting continued demand for hospital services.
Key drivers for the health-care facilities sector include an aging U.S. population that fuels higher inpatient and post-acute care utilization, ongoing Medicare and Medicaid policy adjustments that affect reimbursement rates, and rising health-care inflation that supports pricing power for large, integrated operators like HCA.
For a deeper dive into HCA’s valuation metrics, you might explore the analysis on ValueRay.
Headlines to watch out for
- Hospital admissions volume dictates revenue growth
- Labor costs and staffing shortages impact profitability
- Government healthcare policies influence reimbursement rates
- Acquisition strategy expands market share and patient base
- Interest rate changes affect debt servicing costs
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 6.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 3.19 > 1.0 |
| NWC/Revenue: -3.69% < 20% (prev 1.75%; Δ -5.44% < -1%) |
| CFO/TA 0.21 > 3% & CFO 12.64b > Net Income 6.78b |
| Net Debt (49.16b) to EBITDA (15.60b): 3.15 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (230.7m) vs 12m ago -9.64% < -2% |
| Gross Margin: 41.50% > 18% (prev 0.52%; Δ 4.10k% > 0.5%) |
| Asset Turnover: 125.8% > 50% (prev 118.6%; Δ 7.12% > 0%) |
| Interest Coverage Ratio: 5.37 > 6 (EBITDA TTM 15.60b / Interest Expense TTM 2.25b) |
Altman Z'' 0.64
| A: -0.05 (Total Current Assets 13.56b - Total Current Liabilities 16.35b) / Total Assets 60.72b |
| B: -0.09 (Retained Earnings -5.72b / Total Assets 60.72b) |
| C: 0.20 (EBIT TTM 12.08b / Avg Total Assets 60.12b) |
| D: -0.09 (Book Value of Equity -6.03b / Total Liabilities 63.49b) |
| Altman-Z'' Score: 0.64 = B |
Beneish M -2.69
| DSRI: 0.94 (Receivables 10.87b/10.75b, Revenue 75.60b/70.60b) |
| GMI: 1.24 (GM 41.50% / 51.53%) |
| AQI: 1.36 (AQ_t 0.26 / AQ_t-1 0.19) |
| SGI: 1.07 (Revenue 75.60b / 70.60b) |
| TATA: -0.10 (NI 6.78b - CFO 12.64b) / TA 60.72b) |
| Beneish M-Score: -2.69 (Cap -4..+1) = A |
What is the price of HCA shares?
As of March 21, 2026, the stock is trading at USD 493.88 with a total of 857,305 shares traded.
Over the past week, the price has changed by -7.20%, over one month by -7.08%, over three months by +4.78% and over the past year by +49.08%.
Over the past week, the price has changed by -7.20%, over one month by -7.08%, over three months by +4.78% and over the past year by +49.08%.
Is HCA a buy, sell or hold?
HCA Holdings has received a consensus analysts rating of 4.08.
Therefore, it is recommended to buy HCA.
- StrongBuy: 13
- Buy: 2
- Hold: 9
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HCA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 543.1 | 10% |
| Analysts Target Price | 543.1 | 10% |
HCA Fundamental Data Overview March 20, 2026
P/E Trailing = 17.7278
P/E Forward = 17.094
P/S = 1.485
P/B = 293.44
P/EG = 1.2567
Revenue TTM = 75.60b USD
EBIT TTM = 12.08b USD
EBITDA TTM = 15.60b USD
Long Term Debt = 41.60b USD (from longTermDebt, last quarter)
Short Term Debt = 6.74b USD (from shortTermDebt, last quarter)
Debt = 50.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.16b USD (from netDebt column, last quarter)
Enterprise Value = 161.43b USD (112.27b + Debt 50.20b - CCE 1.04b)
Interest Coverage Ratio = 5.37 (Ebit TTM 12.08b / Interest Expense TTM 2.25b)
EV/FCF = 20.99x (Enterprise Value 161.43b / FCF TTM 7.69b)
FCF Yield = 4.76% (FCF TTM 7.69b / Enterprise Value 161.43b)
FCF Margin = 10.17% (FCF TTM 7.69b / Revenue TTM 75.60b)
Net Margin = 8.97% (Net Income TTM 6.78b / Revenue TTM 75.60b)
Gross Margin = 41.50% ((Revenue TTM 75.60b - Cost of Revenue TTM 44.23b) / Revenue TTM)
Gross Margin QoQ = 41.90% (prev 41.83%)
Tobins Q-Ratio = 2.66 (Enterprise Value 161.43b / Total Assets 60.72b)
Interest Expense / Debt = 1.14% (Interest Expense 572.0m / Debt 50.20b)
Taxrate = 19.05% (509.0m / 2.67b)
NOPAT = 9.78b (EBIT 12.08b * (1 - 19.05%))
Current Ratio = 0.83 (Total Current Assets 13.56b / Total Current Liabilities 16.35b)
Debt / Equity = -8.33 (negative equity) (Debt 50.20b / totalStockholderEquity, last quarter -6.03b)
Debt / EBITDA = 3.15 (Net Debt 49.16b / EBITDA 15.60b)
Debt / FCF = 6.39 (Net Debt 49.16b / FCF TTM 7.69b)
Total Stockholder Equity = -4.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.28% (Net Income 6.78b / Total Assets 60.72b)
RoE = -140.8% (negative equity) (Net Income TTM 6.78b / Total Stockholder Equity -4.82b)
RoCE = 32.84% (EBIT 12.08b / Capital Employed (Equity -4.82b + L.T.Debt 41.60b))
RoIC = 24.33% (NOPAT 9.78b / Invested Capital 40.20b)
WACC = 5.87% (E(112.27b)/V(162.47b) * Re(8.08%) + D(50.20b)/V(162.47b) * Rd(1.14%) * (1-Tc(0.19)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.76%
[DCF] Terminal Value 88.37% ; FCFF base≈6.87b ; Y1≈8.42b ; Y5≈14.11b
[DCF] Fair Price = 1.62k (EV 411.13b - Net Debt 49.16b = Equity 361.97b / Shares 223.6m; r=5.90% [WACC]; 5y FCF grow 24.08% → 2.90% )
EPS Correlation: 89.07 | EPS CAGR: 19.91% | SUE: 1.68 | # QB: 4
Revenue Correlation: 98.76 | Revenue CAGR: 7.37% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-06-30): EPS=7.47 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=19
EPS current Year (2026-12-31): EPS=30.33 | Chg7d=-0.003 | Chg30d=+0.025 | Revisions Net=+11 | Growth EPS=+7.5% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=33.27 | Chg7d=+0.009 | Chg30d=-0.018 | Revisions Net=+5 | Growth EPS=+9.7% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: +0.00 (6 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.4% (Discount Rate 8.1% - Earnings Yield 5.6%)
[Growth] Growth Spread = +1.5% (Analyst 4.0% - Implied 2.4%)
P/E Forward = 17.094
P/S = 1.485
P/B = 293.44
P/EG = 1.2567
Revenue TTM = 75.60b USD
EBIT TTM = 12.08b USD
EBITDA TTM = 15.60b USD
Long Term Debt = 41.60b USD (from longTermDebt, last quarter)
Short Term Debt = 6.74b USD (from shortTermDebt, last quarter)
Debt = 50.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.16b USD (from netDebt column, last quarter)
Enterprise Value = 161.43b USD (112.27b + Debt 50.20b - CCE 1.04b)
Interest Coverage Ratio = 5.37 (Ebit TTM 12.08b / Interest Expense TTM 2.25b)
EV/FCF = 20.99x (Enterprise Value 161.43b / FCF TTM 7.69b)
FCF Yield = 4.76% (FCF TTM 7.69b / Enterprise Value 161.43b)
FCF Margin = 10.17% (FCF TTM 7.69b / Revenue TTM 75.60b)
Net Margin = 8.97% (Net Income TTM 6.78b / Revenue TTM 75.60b)
Gross Margin = 41.50% ((Revenue TTM 75.60b - Cost of Revenue TTM 44.23b) / Revenue TTM)
Gross Margin QoQ = 41.90% (prev 41.83%)
Tobins Q-Ratio = 2.66 (Enterprise Value 161.43b / Total Assets 60.72b)
Interest Expense / Debt = 1.14% (Interest Expense 572.0m / Debt 50.20b)
Taxrate = 19.05% (509.0m / 2.67b)
NOPAT = 9.78b (EBIT 12.08b * (1 - 19.05%))
Current Ratio = 0.83 (Total Current Assets 13.56b / Total Current Liabilities 16.35b)
Debt / Equity = -8.33 (negative equity) (Debt 50.20b / totalStockholderEquity, last quarter -6.03b)
Debt / EBITDA = 3.15 (Net Debt 49.16b / EBITDA 15.60b)
Debt / FCF = 6.39 (Net Debt 49.16b / FCF TTM 7.69b)
Total Stockholder Equity = -4.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.28% (Net Income 6.78b / Total Assets 60.72b)
RoE = -140.8% (negative equity) (Net Income TTM 6.78b / Total Stockholder Equity -4.82b)
RoCE = 32.84% (EBIT 12.08b / Capital Employed (Equity -4.82b + L.T.Debt 41.60b))
RoIC = 24.33% (NOPAT 9.78b / Invested Capital 40.20b)
WACC = 5.87% (E(112.27b)/V(162.47b) * Re(8.08%) + D(50.20b)/V(162.47b) * Rd(1.14%) * (1-Tc(0.19)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.76%
[DCF] Terminal Value 88.37% ; FCFF base≈6.87b ; Y1≈8.42b ; Y5≈14.11b
[DCF] Fair Price = 1.62k (EV 411.13b - Net Debt 49.16b = Equity 361.97b / Shares 223.6m; r=5.90% [WACC]; 5y FCF grow 24.08% → 2.90% )
EPS Correlation: 89.07 | EPS CAGR: 19.91% | SUE: 1.68 | # QB: 4
Revenue Correlation: 98.76 | Revenue CAGR: 7.37% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-06-30): EPS=7.47 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=19
EPS current Year (2026-12-31): EPS=30.33 | Chg7d=-0.003 | Chg30d=+0.025 | Revisions Net=+11 | Growth EPS=+7.5% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=33.27 | Chg7d=+0.009 | Chg30d=-0.018 | Revisions Net=+5 | Growth EPS=+9.7% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: +0.00 (6 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.4% (Discount Rate 8.1% - Earnings Yield 5.6%)
[Growth] Growth Spread = +1.5% (Analyst 4.0% - Implied 2.4%)